Speech highlights the need for inhalation-based prescription nicotine replacement therapy to address efficacy shortfalls of current treatment options RICHMOND, Va., Oct. 21, 2024 /PRNewswire/ -- Qnovia, Inc. announced its CEO is speaking publicly to FDA and NIH at the joint agency public...
Qnovia, Inc. CEO Speaks at FDA and NIH Public Meeting to Encourage Innovation of Smoking Cessation Treatment Options
Seaking AlphaSeeking Alpha / Seaking Alpha 10 hours ago 2 Views
Comments